Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases.
Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases.
复制标题
DOI：
10.1093/trstmh/traa167
复制
发表时间：
2021-01-28
影响因子：
2.2
通讯作者：
Ottesen E
中科院分区：
文献类型：
--
作者：
Bradley M;Taylor R;Jacobson J;Guex M;Hopkins A;Jensen J;Leonard L;Waltz J;Kuykens L;Sow PS;Madeja UD;Hida T;Ole-Moiyoi K;King J;Argaw D;Mohamed J;Polo MR;Yajima A;Ottesen E
被忽视的热带病是全球控制或消除的目标。制药业认识到最需要针对被忽视热带病的药物的人群是那些最没有能力在财政上支持和维持这些疾病的人群，因此建立了通过与世卫组织、发展机构、非政府组织和慈善捐助者建立伙伴关系向受影响国家捐赠药物和专门知识的机制。在过去30年中，各公司制定了捐赠17种不同药物的规划，以克服被忽视的热带病的负担。已捐赠了数十亿片、胶囊、静脉和口服溶液，以及支持这些努力所需的制造、供应链和研究。工业界的参与刺激了其他捐助者通过资金和监督来支持被忽视热带病，从而使对这些规划的投资的“健康效益”回报真正成为“公共卫生领域的最佳价值”。目前的许多捐赠是“开放式的”，承诺只要有必要就提供支持，以实现确定的卫生目标。全球卫生在丝虫病、盘尾丝虫病、沙眼、锥虫病、利什曼病、血吸虫病、肠道寄生虫和其他疾病方面取得了非凡进展；这些进展是在加强卫生系统和实现世卫组织支持的全球发展目标的背景下取得的。制药商在启动或支持这些针对疾病的规划方面已经是强有力的合作者，它们承诺继续发挥伙伴作用，努力实现世卫组织新的2030年非传染性疾病路线图的目标。
Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and expertise to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the ‘heath benefit’ return on investment in these programmes is truly a ‘best value in public health’. Many current donations are ‘open-ended’, promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO's new NTD roadmap to 2030.
登录
查看更多内容
影响因子：
3.8
作者：
Ottesen, Eric A.;Hooper, Pamela J.;Biswas, Gautam
通讯作者：
Biswas, Gautam
影响因子：
9.7
作者：
Gustavsen, Kenneth;Hanson, Christy
通讯作者：
Hanson, Christy
影响因子：
34.3
作者：
Cromwell, Elizabeth A.
通讯作者：
Cromwell, Elizabeth A.
影响因子：
11.8
作者：
Turner, Hugo C.;Bettis, Alison A.;Bradley, Mark H.
通讯作者：
Bradley, Mark H.
影响因子：
2.5
作者：
Williams T;Taylor R;Iwamoto M;Hida T;Gusovsky F
通讯作者：
Gusovsky F